Short interest for Accelerate Diagnostics gives investors a sense of the degree to which investors are betting on the decline of Accelerate Diagnostics's stock. Short interest data is updated every two weeks.

Accelerate Diagnostics Stock (NASDAQ:AXDX), Short Interest Report

Accelerate Diagnostics

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABSI

ADAG

AGAE

AGFY

ALLY

ASTS

AXDX

AZTR

BCDA

BFRG

CELH

CHGG

CISS

CRGE

DTSS

ESPR

EWTX

GOOG

GOOGL

IRBT

KAMN

MESA

MESO

Morgan Stanley Capital Protected Notes for S&P 500 Index

NAMS

NKTX

ORGS

PCSA

PRTG

RNAZ

SAVE

SHPH

SILK

SMCI

SOAR

VMAR

WRLD

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session.

TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share.

TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

doctor-563429

Accelerate Diagnostics shares are trading lower by 38% during Friday&#39;s session. The company priced an underwritten public offering of 6,860,659 units at $1.50 each.

Why Accelerate Diagnostics (AXDX) Stock Is Down 38%

Earnings

Eurozone

Commodities

Global

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday.

Following the market opening Friday, the Dow traded up 0.18% to 37,536.76 while the NASDAQ rose 0.38% to 15,113.04. The S&amp;P 500 also rose, gaining, 0.19% to 4,790.00.

US Stocks Higher; Schlumberger Earnings Beat Estimates

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics Inc

Craig-Hallum analyst Alexander Nowak maintains Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) with a Hold and lowers the price target from $2 to $1.

Price Target

Analyst Ratings

Craig-Hallum Maintains Hold on Accelerate Diagnostics, Lowers Price Target to $1

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Accelerate Diagnostics missed estimated earnings by -44.0%, reporting an EPS of $-0.89 versus an estimate of $-0.62.
Revenue was up $55 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.11 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Accelerate Diagnostics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.07</td>
<td>-1.40</td>
<td>-1.4</td>
<td>-1.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.18</td>
<td>-1.31</td>
<td>-1.7</td>
<td>-1.5</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.53M</td>
<td>3.60M</td>
<td>3.35M</td>
<td>2.87M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.30M</td>
<td>2.92M</td>
<td>2.81M</td>
<td>2.97M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Accelerate Diagnostics <a href="https://www.benzinga.com/quote/AXDX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Accelerate Diagnostics Q4 Earnings

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.62) by 43.55 percent. This is a 493.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $3.03 million which missed the analyst consensus estimate of $3.45 million by 12.26 percent. This is a 1.85 percent increase over sales of $2.97 million the same period last year.

Accelerate Diagnostics Q4 EPS $(0.89) Misses $(0.62) Estimate, Sales $3.03M Miss $3.45M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Universal Stainless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
&bull; Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $158.50 million.
&bull; MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is estimated to report quarterly earnings at $1.16 per share on revenue of $946.55 million.
&bull; Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $33.03 billion.
&bull; Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is projected to report earnings for its fourth quarter.
&bull; Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) is likely to report quarterly loss at $1.68 per share on revenue of $1.71 million.
&bull; Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $168.26 million.
&bull; CNFinance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $65.41 million.
&bull; BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $2.05 billion.
&bull; OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $26.47 million.
&bull; Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $985.30 million.
&bull; Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is projected to report earnings for its fourth quarter.
&bull; Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is expected to report earnings for its fourth quarter.
&bull; DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is projected to report quarterly loss at $0.54 per share on revenue of $3.57 million.
&bull; Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is expected to report earnings for its fourth quarter.
&bull; Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is projected to report earnings for its fourth quarter.
&bull; Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is projected to report earnings for its fourth quarter.
&bull; IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $10.45 million.
&bull; Smart Share Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) is expected to report earnings for its fourth quarter.
&bull; 36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) is projected to report earnings for its fourth quarter.
&bull; 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report quarterly loss at $0.55 per share on revenue of $17.10 million.
&bull; China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $190.26 million.
&bull; D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is projected to report quarterly loss at $0.10 per share on revenue of $4.73 million.
&bull; Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $23.66 million.
&bull; American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) is estimated to report earnings for its fourth quarter.
&bull; Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $1.90 million.
&bull; Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is projected to report earnings for its fourth quarter.
&bull; BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is projected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is estimated to report quarterly loss at $0.44 per share on revenue of $40 thousand.
&bull; Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $11.10 million.
&bull; Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report quarterly loss at $0.08 per share on revenue of $63.50 million.
&bull; Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) is expected to report earnings for its fourth quarter.
&bull; Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $20.40 million.
&bull; Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is projected to report quarterly earnings at $1.95 per share on revenue of $408.18 million.
&bull; Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) is projected to report quarterly loss at $0.38 per share on revenue of $11.33 million.
&bull; Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is expected to report quarterly loss at $0.10 per share on revenue of $1.79 million.
&bull; Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $4.10 million.
&bull; Shapeways Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) is expected to report quarterly loss at $0.95 per share on revenue of $9.25 million.
&bull; NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is expected to report earnings for its fourth quarter.
&bull; CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is projected to report earnings for its fourth quarter.
&bull; Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is expected to report quarterly loss at $5.60 per share on revenue of $3.00 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is projected to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) is expected to report earnings for its fourth quarter.
&bull; Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $11.74 million.
&bull; American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) is projected to report quarterly loss at $0.04 per share on revenue of $2.20 million.
&bull; Vicinity Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $12.62 million.
&bull; Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) is likely to report quarterly loss at $3.77 per share on revenue of $250 thousand.
&bull; Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is likely to report quarterly loss at $0.28 per share on revenue of $25.69 million.
&bull; Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $44.98 million.
&bull; P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.11 per share on revenue of $302.97 million.
&bull; Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) is estimated to report quarterly loss at $0.85 per share on revenue of $200 thousand.
&bull; Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is likely to report quarterly loss at $0.06 per share on revenue of $800 thousand.
&bull; Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $196.46 million.
&bull; Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is likely to report quarterly loss at $0.08 per share on revenue of $274.83 million.
&bull; Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter.
&bull; Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $2.58 per share on revenue of $1.75 million.
&bull; Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is projected to report earnings for its fourth quarter.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is expected to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.28 per share on revenue of $980 thousand.
&bull; Cepton (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) is expected to report quarterly loss at $0.74 per share on revenue of $2.46 million.
&bull; Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $2.14 million.
&bull; Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is estimated to report quarterly loss at $0.45 per share on revenue of $2.54 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $5.56 million.
&bull; Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is estimated to report quarterly loss at $0.62 per share on revenue of $3.45 million.
&bull; Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter.
&bull; Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is projected to report quarterly loss at $0.06 per share on revenue of $58.19 million.
&bull; Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) is likely to report quarterly loss at $1.45 per share on revenue of $9.49 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACHV

ACNT

AFMD

AONC

AREC

ATAT

AZUL

BETR

BOSC

CAAS

CPTN

CURV

DARE

DLPN

DNMR

DOOO

DRIO

DTST

DYAI

FORA

GROY

HSDT

IMCC

IMNN

INLX

INMB

ITRM

JFIN

KRKR

LFLY

NAAS

NDRA

NRXP

NVVE

NXGL

OPRX

PEGY

PIII

PLSE

QBTS

RKDA

SHCR

SHIM

SHPW

SMTC

SRFM

TSAT

USAP

VUZI

WATT

WRAP

XPON

XXII

ZVRA

Earnings Scheduled For March 28, 2024

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.
Analysts estimate that Accelerate Diagnostics will report an earnings per share (EPS) of $-0.62. 
Accelerate Diagnostics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.11, which was followed by a 2.88% drop in the share price the next day.
Here's a look at Accelerate Diagnostics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.07</td>
<td>-1.40</td>
<td>-1.4</td>
<td>-1.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.18</td>
<td>-1.31</td>
<td>-1.7</td>
<td>-1.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>41.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711551682_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Accelerate Diagnostics were trading at $0.9603 as of March 26. Over the last 52-week period, shares are down 86.34%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AXDX/earnings">To track all earnings releases for Accelerate Diagnostics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Accelerate Diagnostics's Earnings

Accelerate Diagnostics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NYSE">AXDX</a>) short percent of float has fallen 26.07% since its last report. The company recently reported that it has 448 thousand shares sold short, which is 2.58% of all regular shares that are available for trading. Based on its trading volume, it would take traders 24.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Accelerate Diagnostics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1706721311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Accelerate Diagnostics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Accelerate Diagnostics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Accelerate Diagnostics's peer group average for short interest as a percentage of float is 1.48%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Accelerate Diagnostics's Recent Short Interest

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares increased by 75.0% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $2.1 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock rose 10.0% to $0.33. The market value of their outstanding shares is at $17.4 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock rose 7.39% to $0.25. The company's market cap stands at $1.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock moved upwards by 6.66% to $1.6. The company's market cap stands at $51.6 million. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) stock moved upwards by 5.04% to $0.67. The market value of their outstanding shares is at $18.1 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares moved upwards by 5.0% to $1.47. The company's market cap stands at $29.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) shares decreased by 10.3% to $7.25 during Tuesday's after-market session. The market value of their outstanding shares is at $269.3 million. </li>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock fell 10.22% to $3.08. The market value of their outstanding shares is at $125.3 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares fell 7.88% to $0.31. The market value of their outstanding shares is at $67.1 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) stock declined by 7.45% to $0.23. The company's market cap stands at $1.5 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 6.51% to $1.15. The company's market cap stands at $2.5 million. </li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares fell 5.7% to $1.49. The market value of their outstanding shares is at $20.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CELU

CNSP

GLTO

IONM

NCNA

ONMD

PTPI

SINT

SLDB

SPRB

12 Health Care Stocks Moving In Tuesday's After-Market Session

Shares of TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) fell sharply during Friday&rsquo;s session.
TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share.
TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Charge Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crge#NASDAQ">CRGE</a>) shares surged 105.4% to $0.2510.</li>
<li>Kaman Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kamn#NASDAQ">KAMN</a>) shares climbed 101.3% to $45.14 after the company announced it will be acquired by Arcline for $1.8 billion.</li>
<li>Mesa Air Group Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mesa#NASDAQ">MESA</a>) gained 70.4% to $1.09 as the company entered into new agreements with United Airlines for improved operating and financing terms.</li>
<li>Edgewise Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ewtx#NASDAQ">EWTX</a>) rose 37.3% to $13.30 after the company announced pricing of its $240 million underwritten offering of 21,818,182 shares at $11 per share.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) climbed 34.2% to $0.2725. Processa Pharmaceuticals announced plans to expand the development of next generation capecitabine (NGC-Cap) into advanced or metastatic breast cancer beginning with next Phase 2 trial in breast cancer.</li>
<li>Tricon Residential Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tcn#NYSE">TCN</a>) shares gained 28.2% to $11.06 Blackstone and Tricon Residential entered into an arrangement agreement under which Blackstone Real Estate Partners X together with Blackstone Real Estate Income Trust, Inc. will acquire all outstanding common shares of Tricon for $11.25 per share in cash.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) jumped 24% to $7.06 after the company announced preliminary fourth-quarter and full year 2023 estimates, issued first-quarter 2024 guidance and said the merger agreement between the company and JetBlue &quot;remains in full force and effect.&quot;</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) climbed 23.1% to $383.31 after the company announced updated financial guidance for the second-quarter, which surpassed its previous outlook.</li>
<li>Allied Gaming &amp; Entertainment Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agae#NASDAQ">AGAE</a>) rose 20.6% to $1.1190.</li>
<li>Portage Biotech Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prtg#NASDAQ">PRTG</a>) gained 19% to $1.14.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmn#NASDAQ">PMN</a>) gained 19% to $2.07.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shph#NASDAQ">SHPH</a>) gained 16.4% to $0.5185.</li>
<li>Treasure Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgl#NASDAQ">TGL</a>) shares rose 14.2% to $0.1176. Treasure Global and AIO Synergy recently entered into a strategic alliance aimed at reshaping the landscape of artificial intelligence.</li>
<li>Silk Road Medical, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/silk#NASDAQ">SILK</a>) jumped 13.1% to $14.91 after Stifel upgraded the stock from Hold to Buy and raised its price target from $9 to $20.</li>
<li>Wayfair Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/w#NYSE">W</a>) jumped 11.6% to $56.81 after the company announced a workforce realignment plan, which includes a workforce reduction involving approximately 13% of its global workforce.</li>
<li>Bullfrog AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfrg#NASDAQ">BFRG</a>) gained 10.6% to $4.30.</li>
<li>NewAmsterdam Pharma Company N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nams#NASDAQ">NAMS</a>) rose 10.5% to $19.44.</li>
<li>World Acceptance Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wrld#NASDAQ">WRLD</a>) gained 10.2% to $134.00 following upbeat quarterly results.</li>
<li>Ally Financial Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ally#NYSE">ALLY</a>) gained 9.4% to $35.15. Synchrony Financial announced plans to acquire Ally Financial&#39;s point of sale financing business. Ally Financial also posted upbeat quarterly sales.</li>
<li>Cyngn Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyn#NASDAQ">CYN</a>) surged 8.8% to $0.1468 after gaining over 5% on Thursday.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) gained 8.1% to $1.86 after the FDA granted a Rare Pediatric Disease Designation to the company&rsquo;s Revascor&reg; for treating children with congenital heart disease.</li>
<li>WNS (Holdings) Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wns#NYSE">WNS</a>) rose 4.4% to $65.71. Needham analyst Mayank Tandon maintained WNS with a Buy and raised the price target from $80 to $85.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) shares fell 63.2% to $0.1384 as the company announced pricing of $7.0 million upsized underwritten public offering.</li>
<li>Azitra, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aztr#NYSE">AZTR</a>) dipped 31.8% to $1.3976 after the company filed for a firm commitment public offering of 3 million shares of common stock.</li>
<li>iRobot Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irbt#NASDAQ">IRBT</a>) fell 30% to $16.53 following a report suggesting the EU plans to block Amazon&#39;s acquisition of the company.</li>
<li>Accelerate Diagnostics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axdx#NASDAQ">AXDX</a>) fell 27.1% to $1.17 after the company reported pricing of approximately $15 million public offering and private placement.</li>
<li>AST SpaceMobile, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asts#NASDAQ">ASTS</a>) declined 24.3% to $3.15. AST SpaceMobile announced a $100 million offering of common stock. The company also announced a strategic investment from AT&amp;T Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>),</li>
<li>Alphabet Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goog#NASDAQ">GOOG</a>) (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) and Vodafone.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) dipped 21.9% to $1.0699. Agrify entered into a multi-million dollar sales agreement with Ocean Deep/Golden Lake Business Park.</li>
<li>Adagene Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adag#NASDAQ">ADAG</a>) fell 21.6% to $2.64.</li>
<li>BioCardia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcda#NASDAQ">BCDA</a>) fell 20% to $0.46.</li>
<li>Volato Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/soar#NYSE">SOAR</a>) fell 17.2% to $2.1688.</li>
<li>Datasea Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtss#NASDAQ">DTSS</a>) shares fell 16.4% to $0.1140. Datasea announced plans for a 1-for-15 reverse stock split to regain compliance with Nasdaq minimum bid requirement.</li>
<li>Orgenesis Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/orgs#NASDAQ">ORGS</a>) dipped 15.3% to $0.2711.</li>
<li>Wheels Up Experience Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/up#NYSE">UP</a>) fell 12.6% to $3.19.</li>
<li>Nkarta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktx#NASDAQ">NKTX</a>) fell 12.2% to $7.47.</li>
<li>Vision Marine Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vmar#NASDAQ">VMAR</a>) shares fell 11.5% to $0.7098. Vision Marine Technologies announced close of $3.0 million private placement of convertible preferred shares and warrants with Investissement Qu&eacute;bec.</li>
<li>Absci Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/absi#NASDAQ">ABSI</a>) dipped 11.3% to $3.2120.</li>
<li>Lithium Americas Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lac#NYSE">LAC</a>) fell 10.4% to $4.3650.</li>
<li>Celsius Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celh#NASDAQ">CELH</a>) fell 10% to $53.60 after B of A Securities downgraded the stock from Buy to Neutral and announced a $65 price target.</li>
<li>Hut 8 Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hut#NYSE">HUT</a>) dipped 9.4% to $6.45.</li>
<li>Lifezone Metals Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lzm#NYSE">LZM</a>) fell 9.3% to $6.37.</li>
<li>MorphoSys AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mor#NASDAQ">MOR</a>) fell 7.3% to $9.49 after falling 6% on Wednesday. Morgan Stanley analyst James Quigley, on Tuesday, downgraded MorphoSys from Overweight to Equal-Weight.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htz#NASDAQ">HTZ</a>) declined 6.6% to $8.40 after Jefferies downgraded the stock from Buy to Hold and lowered its price target from $12 to $8.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) shares fell 6.1% to $2.0188. Esperion priced its $85.1 million public offering of 56.7 million common share at $1.50 per share.</li>
<li>Chegg, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chgg#NYSE">CHGG</a>) shares fell 6.1% to $9.45. Goldman Sachs analyst Eric Sheridan downgraded Chegg from Neutral to Sell and lowered the price target from $10 to $8.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36690939/jim-cramer-predicts-a-terrific-year-for-this-manufacturer-and-as-for-u-haul-im-fine-with"> Jim Cramer Predicts A &#39;Terrific Year&#39; For This Manufacturer, And As For U-Haul? &#39;I&#39;m Fine With It&#39;</a>

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) stock moved upwards by 35.8% to $13.15 during Friday's regular session. The market value of their outstanding shares is at $834.8 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares moved upwards by 32.13% to $5.14. The company's market cap stands at $31.3 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares moved upwards by 23.51% to $0.55. The company's market cap stands at $8.7 million. </li>
<li>NightHawk Biosciences (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHWK#AMEX">NHWK</a>) shares increased by 16.58% to $0.42. The market value of their outstanding shares is at $10.9 million. </li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) shares rose 14.3% to $14.02. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) shares increased by 11.73% to $3.56. The market value of their outstanding shares is at $242.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock declined by 34.0% to $1.06 during Friday's regular session. The company's market cap stands at $15.4 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) shares fell 31.71% to $1.4. The market value of their outstanding shares is at $16.9 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 28.49% to $0.78. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares declined by 23.94% to $0.44. The company's market cap stands at $10.3 million. </li>
<li>Adagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) stock fell 21.37% to $2.65. The market value of their outstanding shares is at $116.1 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock declined by 15.45% to $0.38. The market value of their outstanding shares is at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALVO

NHWK

TNYA

12 Health Care Stocks Moving In Friday's Intraday Session

Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares are trading lower by 38% to $1.00 during Friday&#8217;s session after the company priced an underwritten public offering of 6,860,659 units at $1.50 each, comprising a share of <a href="https://www.benzinga.com/pressreleases/24/01/n36695463/accelerate-diagnostics-announces-pricing-of-approximately-15-million-public-offering-and-private-p">common stock and a warrant</a>.
What Else?
The underwriters have an option for an additional 1,029,098 shares and/or warrants. Warrants are exercisable at $1.65 per share, pre-funded warrants at $0.01 per share, both valid for five years. Gross proceeds are expected to be $10.3 million. 
Concurrently, a private placement to the Jack W. Schuler Living Trust involves the sale of 1,156,069 units at $1.73 per unit, with an agreement for an additional 1,560,693 units. Gross proceeds from the private placement are expected to be $4.7 million. 
The public offering is set to close around January 23, subject to customary conditions. William Blair &amp; Company, L.L.C. is the sole book-running manager, and Craig-Hallum Capital Group LLC is the co-manager.
See Also:&nbsp;<a href="https://www.benzinga.com/news/econ-s/24/01/36695699/feds-goolsbee-expects-interest-rates-to-fall-with-inflation-says-golden-path-is-possible" target="_blank" rel="noreferrer noopener">Fed's Goolsbee Expects Interest Rates To Fall With Inflation</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AXDX has a 52-week high of $11.90 and a 52-week low of $0.95.

WIIM

Accelerate Diagnostics shares are trading lower after the company announced pricing of its roughly $15 million public offering and private placement.

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday.
Following the market opening Friday, the Dow traded up 0.18% to 37,536.76 while the NASDAQ rose 0.38% to 15,113.04. The S&amp;P 500 also rose, gaining, 0.19% to 4,790.00.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36690939/jim-cramer-predicts-a-terrific-year-for-this-manufacturer-and-as-for-u-haul-im-fine-with"> Jim Cramer Predicts A &#39;Terrific Year&#39; For This Manufacturer, And As For U-Haul? &#39;I&#39;m Fine With It&#39;</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Information technology shares rose by 0.6% on Friday.
In trading on Friday, utilities shares fell by 0.3%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Schlumberger Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/slb#NYSE">SLB</a>) posted better-than-expected earnings for its fourth quarter.
SLB posted adjusted earnings of 86 cents per share, beating market estimates of 84 cents per share. The company&rsquo;s quarterly sales came in at $8.99 billion versus expectations of $8.96 billion.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Kaman Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kamn#NASDAQ">KAMN</a>) shares shot up 101% to $45.10 after the company announced it will be acquired by Arcline for $1.8 billion.
Shares of Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) got a boost, surging 38% to $0.2800. Processa Pharmaceuticals announced plans to expand the development of next generation capecitabine (NGC-Cap) into advanced or metastatic breast cancer beginning with next Phase 2 trial in breast cancer.
Tricon Residential Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tcn#NYSE">TCN</a>) shares were also up, gaining 28% to $11.05 Blackstone and Tricon Residential entered into an arrangement agreement under which Blackstone Real Estate Partners X together with Blackstone Real Estate Income Trust, Inc. will acquire all outstanding common shares of Tricon for $11.25 per share in cash.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) shares dropped 65% to $0.1310 as the company announced pricing of $7.0 million upsized underwritten public offering.
Shares of Accelerate Diagnostics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axdx#NASDAQ">AXDX</a>) were down 38% to $0.9901 after the company reported pricing of approximately $15 million public offering and private placement.
iRobot Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irbt#NASDAQ">IRBT</a>) was down, falling 29% to $16.74 following a report suggesting the EU plans to block Amazon&#39;s acquisition of the company.
Also Check This Out:<a href="https://www.benzinga.com/news/24/01/36694225/top-3-financial-stocks-that-may-implode-in-q1"> Top 3 Financial Stocks That May Implode In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.4% to $74.35 while gold traded up 0.5% at $2,032.30.
Silver traded down 0.3% to $22.74 on Friday while copper rose 0.6% to $3.7670.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.2%, London&rsquo;s FTSE 100 rose 0.2% while Spain&rsquo;s IBEX 35 Index fell 0.1% The German DAX fell 0.2% French CAC 40 fell 0.143% while Italy&rsquo;s FTSE MIB Index fell 0.1%.
Producer prices in Germany declined 8.6% year-over-year in December compared to a 7.9% fall in the previous month. Retail sales in the UK fell by 3.2% in December compared to a revised 1.4% rise in the prior month.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Friday, with Japan&rsquo;s Nikkei 225 gaining 1.40%, Hong Kong&rsquo;s Hang Seng Index falling 0.54% and China&rsquo;s Shanghai Composite Index declining 0.47%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.70%.
Foreign direct investment into China declined by 8% year-over-year to CNY 1.13 trillion ($157.1 billion) in 2023. The business confidence indicator in Hong Kong declined to +1 in the first quarter versus a reading of +8 in the prior three-month period. The annual inflation rate in Japan slowed to 2.6% in December from 2.8% in the earlier month, recording the lowest reading since July 2022.
&nbsp;
<h3>Economics</h3>
&nbsp;
Data on existing home sales will be released at 10:00 a.m. ET.
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36690876/how-to-earn-500-a-month-from-at-t-stock-ahead-of-q4-print"> How To Earn $500 A Month From AT&amp;T Stock Ahead Of Q4 Print </a>

Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) (the "Company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and for certain investors in lieu thereof, pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock. The public offering price for each unit is $1.50 and the public offering price for each pre-funded unit is $1.49. The Company granted the underwriters a 30-day option to purchase up to an additional 1,029,098 shares of common stock and/or additional warrants to purchase up to 1,029,098 shares of common stock, in any combination thereof, at the public offering price, less underwriting discounts and commissions.
The warrants will have an exercise price of $1.65 per share, will be immediately exercisable and will remain exercisable until the date that is five years after their original issuance. The pre-funded warrants will have an exercise price of $0.01 per share, will be immediately exercisable and will remain exercisable until exercised in full. The gross proceeds from the public offering, before deducting underwriting discounts and commissions and other public offering expenses payable by the Company, are expected to be $10.3 million (excluding any proceeds that may be received upon the exercise of the warrants or the pre-funded warrants). The public offering is expected to close on or about January 23, 2024, subject to the satisfaction of customary closing conditions.
Concurrently with the completion of the public offering, the Company will sell, subject to certain closing conditions, to the Jack W. Schuler Living Trust ((the largest shareholder of the Company and an entity affiliated with Jack W. Schuler, a director of the Company, the "Trust") in a private placement, 1,156,069 units at a purchase price of $1.73 per unit. In addition, the Trust has agreed to purchase an additional 1,560,693 units at a purchase price of $1.73 per unit on or before May 20, 2024. The gross proceeds from the private placement, before deducting private placement expenses payable by the Company, are expected to be $4.7 million (excluding any proceeds that may be received upon the exercise of the warrants).
William Blair &amp; Company, L.L.C. is acting as the sole book-running manager and Craig-Hallum Capital Group LLC is acting as co-manager.
A registration statement on Form S-1 (File No. 333-276031) relating to the public offering was declared effective by the Securities and Exchange Commission (the "SEC") on January 19, 2024. The public offering is being made only by means of a prospectus. Copies of the final prospectus relating to the public offering, may be obtained, when available, from: William Blair &amp; Company, L.L.C. at 150 North Riverside Plaza, Chicago, Illinois 60606, Attention: Prospectus Department, by telephone at (800) 621-0687, or by email at <a href="mailto:prospectus@williamblair.com">prospectus@williamblair.com</a>.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Offerings

Accelerate Diagnostics Announces Pricing Of ~$15M Public Offering And Private Placement; The Public Offering Price For Each Unit Is $1.50 And The Public Offering Price For Each Pre-Funded Unit Is $1.49

<h3>Gainers</h3>
<ul>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares increased by 22.1% to $2.1 during Friday's pre-market session. The company's market cap stands at $180.2 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock rose 20.27% to $0.5. The company's market cap stands at $88.6 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock increased by 19.27% to $0.37. The market value of their outstanding shares is at $11.1 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) stock rose 17.43% to $1.28. The company's market cap stands at $3.1 million. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) stock increased by 14.99% to $2.76. The market value of their outstanding shares is at $307.3 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares increased by 14.35% to $2.43. The company's market cap stands at $1.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) stock fell 17.7% to $1.77 during Friday's pre-market session. The market value of their outstanding shares is at $201.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock declined by 15.47% to $1.1. The market value of their outstanding shares is at $1.3 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares fell 10.91% to $1.43. The market value of their outstanding shares is at $20.8 million. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) stock declined by 9.47% to $0.12. The company's market cap stands at $29.9 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock decreased by 9.12% to $0.41. The company's market cap stands at $1.3 million. </li>
<li>MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) stock declined by 8.7% to $9.35. The market value of their outstanding shares is at $1.4 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

CHRS

INVO

NUWE

SGMO

TBIO

TCBP

TCRT

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) shares rose 37.5% to $0.77 during Tuesday's regular session. The company's market cap stands at $117.0 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock increased by 31.32% to $106.4. The company's market cap stands at $832.8 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) stock increased by 26.08% to $1.17. The company's market cap stands at $82.5 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock rose 21.55% to $2.03. The company's market cap stands at $30.1 million. </li>
<li>MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) stock increased by 20.81% to $10.39. The company's market cap stands at $1.5 billion. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock rose 17.55% to $1.41. The company's market cap stands at $17.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) shares fell 58.5% to $1.24 during Tuesday's regular session. The company's market cap stands at $108.4 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares fell 26.49% to $2.72. The market value of their outstanding shares is at $39.5 million. </li>
<li>Atreca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) shares fell 26.46% to $0.26. The company's market cap stands at $10.3 million. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) stock fell 25.2% to $0.43. The company's market cap stands at $120.6 million. </li>
<li>ASLAN Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLN#NASDAQ">ASLN</a>) stock fell 19.62% to $0.76. The company's market cap stands at $12.6 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) shares decreased by 17.49% to $4.72. The company's market cap stands at $3.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

ALLK

ASLN

AVTX

BCEL

CATX

EKSO

VXRT

ZJYL

12 Health Care Stocks Moving In Tuesday's Intraday Session

Accelerate Diagnostics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares are trading lower by 23.2% to $2.84 Tuesday morning after the company announced the initiation of a proposed underwritten public offering of <a href="https://www.benzinga.com/pressreleases/24/01/n36638137/accelerate-diagnostics-announces-launch-of-proposed-public-offering">4.5 million units</a>. 
What Else?
Each unit comprises one share of common stock and one warrant to purchase one share of common stock. Alternatively, certain investors may opt for pre-funded units, which include one pre-funded warrant to purchase one share of common stock and one regular warrant.
The company anticipates granting the underwriters a 30-day option to acquire up to an additional 675,000 shares of common stock and/or additional warrants. The completion and specific terms of the offering are contingent on market and other conditions, with no guaranteed assurance of completion or final size.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36640167/no-recession-in-2024-institutional-investors-long-on-magnificent-7-small-caps">No Recession In 2024? Institutional Investors Long On Magnificent 7, Small Caps</a>
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AXDX has a 52-week high of $11.90 and a 52-week low of $2.76.

Why Accelerate Diagnostics (AXDX) Stock Hit A New 52-Week Low Today

Accelerate Diagnostics shares are trading lower after the company announced the launch of a proposed public offering.

<h3>Gainers</h3>
<ul>
<li>MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) shares moved upwards by 15.1% to $9.9 during Tuesday's pre-market session. The company's market cap stands at $1.4 billion. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) shares increased by 14.45% to $1.9. The market value of their outstanding shares is at $40.4 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares increased by 14.01% to $1.22. The market value of their outstanding shares is at $27.8 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) stock moved upwards by 13.82% to $0.28. The company's market cap stands at $1.8 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares moved upwards by 13.75% to $3.97. The market value of their outstanding shares is at $64.3 million. </li>
<li>Societal CDMO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCTL#NASDAQ">SCTL</a>) stock increased by 11.49% to $0.39. The company's market cap stands at $40.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock fell 56.5% to $1.3 during Tuesday's pre-market session. The company's market cap stands at $113.7 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares fell 16.22% to $3.1. The company's market cap stands at $45.1 million. </li>
<li>Atreca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) stock declined by 14.88% to $0.3. The market value of their outstanding shares is at $12.0 million. </li>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) shares decreased by 13.65% to $0.69. The company's market cap stands at $26.1 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares decreased by 12.42% to $3.88. The company's market cap stands at $200.3 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock declined by 10.64% to $0.42. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

EVAX

GANX

MODD

SCTL

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

The Company expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock and/or additional warrants to purchase up to 675,000 shares of common stock
The Company expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock and/or additional warrants to purchase up to 675,000 shares of common stock

Health Care

Financing

General

Accelerate Diagnostics Has Launched A Proposed Underwritten Public Offering Of 4.5M Each Consisting Of One Share Of Common Stock And One Warrant To Purchase One Share Of Common Stock; Terms Not Disclosed

Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2023.
<a href="https://mma.prnewswire.com/media/727214/Accelerate_Diagnostics_Logo.html"><img src="https://mma.prnewswire.com/media/727214/Accelerate_Diagnostics_Logo.jpg" alt="Accelerate Diagnostics, Inc. (PRNewsfoto/Accelerate Diagnostics)" /></a>
"In 2023, we made significant progress with the development of our next-generation rapid Antimicrobial Susceptibility Testing system, Accelerate WaveTM. We continue to advance this important development program and remain on plan to begin our clinical trials in the second quarter of 2024," commented&nbsp;Jack Phillips, President and CEO of Accelerate Diagnostics,&nbsp;Inc.&nbsp; "In addition, we continue to expand and secure our Pheno&#xAE; customer base, with an upgrade path to Wave&nbsp;adoption.&nbsp;Based on consistent customer feedback, Wave is anticipated to set the new standard for rapid, same-shift, susceptibility testing," Mr. Phillips continued.
2023 Fourth Quarter Operational Results
<ul>
<li>Notable Wave program achievements during the quarter included:
<ul>
<li>Completed Wave system integration.&nbsp;</li>
<li>Significantly advanced AST performance of gram-negative positive blood culture menu for approximately 250 bug-drug combinations and running approximately 3,000 unique strains of gram-negative organisms with average time-to-results below 4.5 hours.</li>
</ul>
</li>
<li>Completed extensive reviews with U.S. and EMEA customers to validate Wave's product specifications and menu roll-out strategy. Approximately 90% of customers have expressed interest in adopting Accelerate Wave for both rapid positive blood culture and isolated colony testing given unique perceived benefits compared to existing and emerging automated susceptibility platforms.</li>
<li>In the US, added six new contracted&nbsp;Pheno instruments during the quarter, ending the quarter with 340 clinically live Pheno revenue-generating instruments and another 71 contracted Pheno instruments in the process of being implemented.</li>
<li>Executed a collaboration and quality agreement with Bruker Corporation for the Accelerate ArcTM system, made significant progress towards completing the U.S. clinical trial and anticipate submission to the FDA during the first quarter of 2024.</li>
</ul>
Preliminary 2023 Full Year Results
<ul>
<li>Secured approximately 65% of current U.S. Pheno customers to multi-year contracts for rapid susceptibility testing, reflecting customers' commitment to Accelerate rapid AST technology and interest in Wave.</li>
<li>Preliminary revenue was approximately $12.1 million for the year, compared to $12.8 million in the prior year. While year-over-year revenues for consumable products increased by approximately 5%, overall annual revenue was down year-over-year due to a challenging capital sales environment in all our sales regions.</li>
<li>Ended the year with approximately $13.4 million in cash and cash equivalents, representing net cash used in the fourth quarter of approximately $7.8 million. This reflects a continued reduction in operating cash use over the prior quarters of 2023, following cost cutting measures implemented throughout 2023.</li>
</ul>
The preliminary results set forth above are unaudited, are based on management's initial review of Accelerate's&nbsp;results as of and for the year ended December 31, 2023, and are subject to revisions based upon Accelerate's&nbsp;year-end closing procedures and the completion of the external audit of Accelerate's&nbsp;year-end financial statements. Actual results may differ materially from these preliminary unaudited results as a result of the completion of year-end closing procedures, final adjustments and other developments arising between now and the time that Accelerate's&nbsp;financial results are finalized. In addition, these preliminary unaudited results are not a comprehensive statement of Accelerate's financial results for the year ended December 31, 2023, should not be viewed as a substitute for full, audited financial statements, prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the Company's results for any future period. Accordingly, investors are cautioned not to place undue reliance on these preliminary unaudited results.
Accelerate expects to announce full-year 2023 financial results in advance of its earnings conference call in March 2024.&nbsp;

Accelerate Diagnostics Announces Certain Preliminary Q4 And FY23 Results; FY23 Preliminary Revenue Was ~$12.1M Vs $12.8M YoY; Ended The Year With ~$13.4M In Cash And Cash Equivalents

Accelerate Diagnostics Inc (AXDX) stock has fallen 11.11% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator. Accelerate Diagnostics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AXDX!See Full AXDX ReportWhat is Stock Sentiment

Should You Buy Accelerate Diagnostics Inc (AXDX) Stock After it Is Down 11.11% in a Week?

Accelerate Diagnostics Inc (AXDX) stock is up 16.48% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Accelerate Diagnostics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AXDX!See Full AXDX ReportWhat is Stock Sentiment?Sent

How Will the Market React to Accelerate Diagnostics Inc (AXDX) Stock Getting a Bullish Rating

Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more

Accelerate Diagnostics Inc (AXDX) stock has fallen -80.83% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver's proprietary ranking system, gives AXDX stock a score of  34 out of a possible 100. That rank is primarily influenced by a long-term technical score of 2. AXDX's

Accelerate Diagnostics Inc (AXDX) Stock Loses -2.02% This Week; Should You Buy?

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accelerate Diagnostics Stock (NASDAQ:AXDX), Short Interest Report

People Also Watch